Home>Topics>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1-Regeneron revenue beats Street on strong Eylea sales

      Headlines

      Tue, 10 Feb 2015

      Feb 10 (Reuters) - Regeneron Pharmaceuticals Inc reported better-than-expected fourth-quarter sales, driven by surging demand for its blockbuster eye drug Eylea.

    2. Regeneron's profit rises about 14 pct on strong Eylea sales

      Headlines

      Tue, 10 Feb 2015

      Feb 10 (Reuters) - Regeneron Pharmaceuticals Inc reported a nearly 14 percent jump in quarterly profit, driven by strong demand for its blockbuster eye drug Eylea.

    3. Regeneron/Sanofi cholesterol drug gets FDA priority review

      Headlines

      Mon, 26 Jan 2015

      Jan 26 (Reuters) - Regeneron Pharmaceuticals on Monday said U.S. health regulators accepted its application to review a potent cholesterol drug on a priority basis, potentially

    4. From Barron’s, January 5, 2015 (Part 1)

      Commentary

      Sat, 3 Jan 2015

      Holdings [ CPA ] is attractive for a rebound play. Strong large-cap performers with significant insider activity include KMI, REGN , RSG, VRX, CHTR, DVA, TWX . For the week , DJIA -1.22% , SP500 -1.46% , Nasdaq Comp -1.67% , Russell 2000

    5. A Biotech With a Growing Moat

      Video Reports

      Wed, 31 Dec 2014

      Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company that we rate as having a narrow moat and a positive moat trend. We think its positive moat trend

      REGN found at 0:03

      Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company that we rate as having a narrow moat and a positive moat trend. We think its positive moat
    6. REGN

      Commentary

      Tue, 25 Nov 2014

      Can anyone provide some insight on why they think this company would be a Great Investment? Thank you for the input!

    7. Sifting Through Fidelity's Large-Cap Medalists

      Headlines

      Thu, 3 Apr 2014

      Some of his biggest winners in recent years are shares he bought years ago when they were much smaller, including Regeneron REGN and Salesforce.com CRM. Wymer has beaten large-growth peers during his tenure, albeit with greater volatility. Wymer doesn

    8. From Barron’s, March 31, 2014 (Part 2)

      Commentary

      Sat, 29 Mar 2014

      relative to sectors such as IT that require lesser capex. Some highflyers sank last week, e.g. biotechs [ ALXN, CELG, GILD, REGN ] and other momentum favorites [ GMCR, FB, TWTR, P, YELP, NFLX, BIDU ]; fears of higher rates and weaker economy were

    9. From Barron’s, March 24, 2014 (Part 2)

      Commentary

      Sat, 22 Mar 2014

      Isaly , the manager of Eaton Vance health sciences ETHSX . He still likes biotechs and pharma. His picks are AGN, ESRX, ISRG, REGN , RHHBY ; also mentioned are BIIB, GILD, PCYC, MDVN, ALPMY, ABBV, JAZZ, PRGO, ACT, JNJ, BMY, MRK, A . Pg 30: Electronic

    10. FDA probes cognitive impact of new cholesterol drugs

      Headlines

      Fri, 7 Mar 2014

      (Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...

    « Prev12345Next »
    Content Partners